CDK4 and prostate cancer: At present, three CDK4/6 inhibitors (CDK4/6i) Palbociclib, Ribociclib and Abemaciclib are FDA-approved and are further evaluated in clinical trials in several cancers, including breast cancer, non-small and small cell lung cancer, and prostate cancer [59].